Most health expert recommend six month of exclusive breastfeeding but statics suggest that numbers are not good, almost 95% mothers start breastfeeding but this number drops to 40% in first three month and further it drops to 15% till fifth month. Sometime its due to need of medication usage. Because of these statics its important to provide good information on safety of drugs in breastfeeding so that it can be improved when possible. In this FAQ sheet we will discuss about exposure to Morphabond Er | Morphine Sulfate Tablet, Extended Release while breastfeeding. We will also discuss about common side effects and warnings associated with Morphabond Er | Morphine Sulfate Tablet, Extended Release.
What is Morphabond Er | Morphine Sulfate Tablet, Extended Release used for?
MORPHABOND ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions ( 5.1 )], reserve MORPHABOND ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. MORPHABOND ER is not indicated as an as-needed (prn) analgesic. MORPHABOND ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (1) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve MORPHABOND ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. (1) MORPHABOND ER is not indicated as an as-needed (prn) analgesic. (1)
Is Morphabond Er | Morphine Sulfate Tablet, Extended Release safe to use while breastfeeding? Can it interfere with growth and development of my kid?
Morphine sulfate is the one and only active ingredient present in Morphabond Er | Morphine Sulfate Tablet, Extended Release. Morphine sulfate in itself is a low risk drug for lactation so it is easy to understand that Morphabond Er | Morphine Sulfate Tablet, Extended Release also comes in category of Low Risk item while breastfeeding. Below is the summary of Morphine sulfate in breastfeeding.
Morphabond Er | Morphine Sulfate Tablet, Extended Release Breastfeeding Analsys
Low RiskCAS Number: 57-27-2
Excretion into breast milk is low (even lower when administered through Epidural Anesthesia). In addition, a low oral bioavailability makes that the amount present in the infant's plasma due to absorption from milk by the gut is low. Even though, level of drug has been found in the plasma of infants from treated mothers, harmful effects in the infants were not reported. Levels in the milk are lower and side-effects are fewer among infants whose mothers were treated with Morphine than with Pethidine. Some authorities consider Morphine as the elective opioid medication for breastfeeding mothers. Analgesia used during the birth process is related to a brief delayed of stage II of Lactogenesis (milk come-in). Morphine increases Prolactin level and may decrease Oxytocin level, but it would not be determinant for already established lactations. Avoidance of repetitive or chronic use and follow-up for somnolence and adequacy of infant nourishment is recommended. Bed-sharing should be avoid whenever this medication is used by parents. The American Academy of Pediatrics rates it as compatible with breastfeeding.
Morphabond Er | Morphine Sulfate Tablet, Extended Release Breastfeeding Analsys - 2
CAS Number: 57-27-2
Epidural morphine given to mothers for postcesarean section analgesia results in trivial amounts of morphine in their colostrum and milk. Intravenous or oral doses of maternal morphine in the immediate postpartum period result in higher milk levels than with epidural morphine. Labor pain medication may delay the onset of lactation. Maternal use of oral narcotics during breastfeeding can cause infant drowsiness, central nervous system depression and even death, although low-dose morphine might be preferred over other opiates.[1] Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. Once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of morphine to a 2 to 3 days at a low dosage with close infant monitoring, especially in the outpatient setting.[2] If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately.
What should I do if already breastfed my kid after using Morphabond Er | Morphine Sulfate Tablet, Extended Release?
Morphabond Er | Morphine Sulfate Tablet, Extended Release is in the category of low risk, if you have already used it then its not a big deal if health and behavior of baby is good. However your health care provider shall be aware of the fact that you have used Morphabond Er | Morphine Sulfate Tablet, Extended Release so you should inform him based on your convenience.
My health care provider has asked me to use Morphabond Er | Morphine Sulfate Tablet, Extended Release, what to do?
Morphabond Er | Morphine Sulfate Tablet, Extended Release comes in category of low risk and if your doctor is aware that you are breastfeeding it should be ok to use without much concerns.
If I am using Morphabond Er | Morphine Sulfate Tablet, Extended Release, will my baby need extra monitoring?
Not much monitoring required while using Morphabond Er | Morphine Sulfate Tablet, Extended Release
Who can I talk to if I have questions about usage of Morphabond Er | Morphine Sulfate Tablet, Extended Release in breastfeeding?
US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week
Drug Brands with same Active ingredients